Point72 Asset Management L.P. Cuts Stock Position in BioNTech SE (NASDAQ:BNTX)

Point72 Asset Management L.P. lowered its holdings in BioNTech SE (NASDAQ:BNTX) by 21.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 361,993 shares of the company’s stock after selling 99,718 shares during the period. Point72 Asset Management L.P.’s holdings in BioNTech were worth $42,994,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of BNTX. Tidal Investments LLC purchased a new position in BioNTech in the first quarter worth $703,000. EverSource Wealth Advisors LLC boosted its position in BioNTech by 106.3% in the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after purchasing an additional 252 shares during the last quarter. GAMMA Investing LLC boosted its position in BioNTech by 86.9% in the second quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock worth $41,000 after purchasing an additional 238 shares during the last quarter. Granite Bay Wealth Management LLC purchased a new position in BioNTech in the second quarter worth $1,483,000. Finally, Baader Bank Aktiengesellschaft boosted its position in BioNTech by 4.2% in the second quarter. Baader Bank Aktiengesellschaft now owns 140,750 shares of the company’s stock worth $11,258,000 after purchasing an additional 5,650 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Trading Down 0.8 %

Shares of BNTX stock opened at $114.70 on Thursday. The stock has a market capitalization of $27.50 billion, a PE ratio of -54.62 and a beta of 0.22. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49. The business has a 50-day moving average of $113.83 and a 200 day moving average of $99.12. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. During the same quarter last year, the business posted $0.73 EPS. The business’s revenue was up 38.9% on a year-over-year basis. As a group, sell-side analysts anticipate that BioNTech SE will post -3.72 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Jefferies Financial Group raised BioNTech from a “hold” rating to a “buy” rating and upped their price target for the company from $96.00 to $150.00 in a research report on Tuesday, September 17th. Deutsche Bank Aktiengesellschaft upped their price target on BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, September 19th. UBS Group upped their price target on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research report on Wednesday, September 18th. Evercore ISI upgraded BioNTech from an “in-line” rating to an “outperform” rating and boosted their price objective for the company from $110.00 to $125.00 in a research note on Tuesday, November 19th. Finally, HC Wainwright restated a “buy” rating and issued a $150.00 target price on shares of BioNTech in a research note on Monday, November 18th. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $138.67.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.